In vitro susceptibility of Mycobacterium kansasii to the difluorinated quinolone sparfloxacin using a broth microdilution and macrodilution MIC system

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 4, 1999, Pages 349-353

  Royo, P ^a   Martín Casabona, Nuria ^a,b   Martinez, E ^a   Andonegui, M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

M. kansasii; Microdilution susceptibility tests; Sparfloxacin

Indexed keywords

SPARFLOXACIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BACTERIUM ISOLATION; DILUTION; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM KANSASII; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; STRAIN DIFFERENCE;

ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM KANSASII;

EID: 0345369559     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Lillo M, Orengo S, Cernoch P, Harris R L. Pulmonary and disseminated infection due to M. kansasii: a decade of experience. Rev Infect Dis 1990; 12: 760-767.
2. Patel R, Roberts G D, Keating M R, Paya C V. Infections due to non-tuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 1994; 19: 263-273.
3. Skogberg K, Ruutu P, Tukiainen P, Valtonen V V. Nontuberculous mycobacterial infection in HIV-negative patients receiving immunosuppressive rherapy. Eur J Clin Microbiol Infect Dis 1995; 14: 755-763.
4. Bamberger D, Dirks M R, Gupta M R, O'Connor M C, Jost P M. M. kansasii among patients infected with human immunodeficiency virus in Kansas City. Clin Infect Dis 1994; 18: 395-400.
5. Witzig R S, Fazal B A, Mera R M, et al. Clinical manifestations and implications of coinfection with M. kansasii and human immunodeficiency virus type 1. Clin Infect Dis 1995; 21: 77-85.
6. American Thoracic Society. Diagnosis and treatment of disease caused by non-tuberculous mycobacteria. Am Rev Respir Dis 1990; 142: 940-953.
7. Breathnach A, Lewell N, Munro C, Natarajan S, Pedler S. Cutaneous Mycobacterium kansasii infection: case report and review. Clin Infect Dis 1995; 20: 812-817.
8. Chai H A, Wallace R J, Steele L C, Murphy D T. Sulfonamide-containing regimens for disease caused by rifampicin-resistant M. kansasii. Am Rev Respir Dis 1987; 135: 10-16.
9. Dautzenberg B, Antoun F, Truffot C H. Résistance acquise à la rifampicine dans le cours d'une infection à M. kansasii en un patient atteint de SIDA. Rev Mal Respir 1992; 9: 464-466.
10. Davidson P T, Wagganer R. Acquired resistance to rifampin by M. kansasii. Tubercle 1976; 57: 271-273.
11. Wallace R J, Dunbar D, Brown B A, et al. Rifampin-resistant M. kansasii. Clin Infect Dis 1994; 8: 736-743.
12. Richard P, Gutmann L. Sparfloxacin and other new fluoroquinolones. J Antimicrob Chemother 1992; 30: 739-744.
13. Phillips I, Acar J, Baquero F, et al. European study group on antibiotic breakpoints. Breakpoint determination: sparfloxacin. Eur J Clin Microbiol Infect Dis 1994; 13: 283-284.
14. Martin-Luengo F, Sempere M A. Activity of sparfloxacin and other quinoloncs against mycobacteria. Drugs 1993; 45 (Suppl 2): 219-220.
15. Wallace R J, Nash D R, Steele L C, Steingrube V. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol 1986; 24: 976-981.
16. Telles M A S, Yates M D. Single and double drug susceptibility testing of Mycobacterium avium complex and mycobacteria other than the tubercle (MOTT) bacilli by a microdilution broth minimum inhibitory concentration (MIC) method. Tubercle Lung Dis 1994; 75: 286-290.
17. Martín-Casabona N, González T, Fernández F. Micobacteriosis: presentación de 38 casos. Med Clin (Barc) 1985; 84: 651-654.
18. Horsburgh C R Jr, Selik R M. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139: 4-7.
19. British Thoracic Society. M. kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Thorax 1994; 49: 442-445.
20. Hopewell P, Cynamon M, Starke J, Iseman M, O'Brien R. Evaluation of new anti-infective drugs for the treatment of disease caused by M. kansasii and other mycobacteria. Clin Infect Dis 1992; 15: 307-312.
21. Rubio M I, Álvarez C, Pompeyo V, Martínez F. Shock anafiláctico mortal por rifampicina en un paciente con infección por HIV. Enf Microbiol Clin 1996; 14: 200-201.
22. Rastogi N, Labrousse V, Khye Seng Gonh. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against M. avium complex growing extracellularly and intracellularly in murine and human macrophages. Antimicrob Agents Chemother 1991; 35: 2473-2480.
23. Leysen D C, Haemers A, Pattyn S R. Mycobacteria and the new quinolones. Antimicrob Agents Chemother 1989; 33: 1-5.
24. Jacobs M R. Activity of quinolones against mycobacteria. Drugs 1995; 49 (Suppl 2): 67-75.
25. Sempere M A, Valero-Guillem P L, Martín-Luengo F, Ruiz-Gómez J. Effects of sparfloxacin on complex lipids of M. fortuitum. Rev Esp Quimioterap 1994; 7: 134-136.
26. Patil M A, Katoch V M, Venkatesan K, Sharma V D. Correlation between inhibitory effect of quinolones and mycolic acid metabolism in mycobacteria. J Lepr 1992; 64: 331-340.
27. Pechere J C. Quinolones in intracellular infections. Drugs 1993; 45 (Suppl 3): 29-36.
28. Witzig R S, Franzblau S G. Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin and fusidic acid. Antimicrob Agents Chemother 1993; 9: 1997-1999.
29. Brown B A, Wallace R J, Onyi G O. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 1992; 36: 1987-1990.